Pregabalin Capsule
Product Images NDC 50090-5038

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-5038). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905038)

Pregabalin 75 mg capsules packaging label from A-S Medication Solutions. The label displays the NDC number 50090-5038-0, product and lot numbers, and storage instructions to keep at 77 degrees Fahrenheit. The container holds 90 capsules with a prescription-only designation. Dosage details refer to the package insert.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart depicting percent of patients improved versus percent improvement in pain from baseline. It compares four groups receiving Pregabalin at 200 mg, 100 mg, and 25 mg three times a day, and a placebo group, showing differences in patient improvement rates across medication dosages and placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares two groups: patients taking Pregabalin 100 mg three times a day and placebo, showing higher improvement percentages in the Pregabalin group across the range.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg taken twice a day, compared with placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents percent of patients improved. Lines indicate higher doses of Pregabalin correspond to greater improvements than placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating the effectiveness of Pregabalin doses relative to placebo in improving patient pain.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing the distribution of pain improvement percentages among patients.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

Bar graph showing responder rates in percentage for Studies E1 and E3 comparing different doses of pregabalin to placebo. Study E1 includes placebo and daily doses of 50 mg, 150 mg, 300 mg, and 600 mg, with responder rates increasing from 14% for placebo up to 51% for 600 mg/day. Study E3 compares placebo, 300 mg/day (BID), and 600 mg/day (TID) doses with responder rates of 9%, 43%, and 49% respectively. The graph notes statistical significance versus placebo at various points.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A graph showing seizure reduction as median percent change from baseline versus dose in mg/day. The chart compares four different studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, each represented by different markers. P-values indicating statistical significance are displayed for various dose points. A note mentions zero dose corresponds to placebo, and only significant p-values are shown.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent improvement in pain from baseline on the horizontal axis and percent of patients improved on the vertical axis. The graph compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, illustrating trends in patient improvement by dose.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A survival curve comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The graph shows a higher percentage of subjects without LTR on Pregabalin across the timeline compared to placebo, with the y-axis representing estimated percentage and the x-axis representing days.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12 using the BOCF method for Pregabalin versus placebo. The x-axis shows percent improved from 0 to 100, and the y-axis shows percent of subjects improved from 0% to 100%. Pregabalin shows a higher percent of subjects improved compared to placebo throughout the graph.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph depicting the percent of subjects improved from baseline to week 16 using baseline observation carried forward (BOCF). The x-axis shows the percent improved from greater than 0 to 100, while the y-axis shows the percent of subjects improved from 0 to 100. Two lines represent the treatment groups: a solid line for Pregabalin and a dashed line for Placebo, with the Pregabalin group showing a higher percentage of subjects improved across most ranges.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel showing a formula for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine levels, with an adjustment factor for female patients. This panel appears to provide pharmacokinetic or dosing calculation information related to the drug Pregabalin 75 mg capsules by A-S Medication Solutions.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin depicting its molecular arrangement with a carboxyl group (CO2H) and an amino group (NH2), consistent with the active ingredient in Pregabalin capsules from A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.